Practical considerations for chimeric antigen receptor design and delivery. Expert Opin Biol Ther 2017 Aug;17(8):961-978
Date
06/07/2017Pubmed ID
28586264DOI
10.1080/14712598.2017.1339687Scopus ID
2-s2.0-85023630131 (requires institutional sign-in at Scopus site) 15 CitationsAbstract
The development of chimeric antigen receptor (CAR)-modified immune cells has become a highly active field of research since the introduction of this approach in 1989. New ideas are constantly being proposed and tested, resulting in CARs that are more effective and specialized. Areas covered: Many aspects of CAR design and administration can be varied in order to achieve the best possible outcomes; optimization of this therapeutic schema is an active area of research. Here, the authors summarize the work that has been carried out thus far to assess different adaptations for each portion of the CAR itself. They also discuss the various methods used for CAR transgene transfer into effector cells. Expert opinion: While the field has made significant advancements in terms of expansion and testing of the variations available for CAR therapy, it remains difficult to ascertain which options are truly superior and under what conditions. Continued research in this area, as well as in aspects such as improving the safety profile and the anti-tumor potency of CARs, will be required to bring this therapy from early-phase clinical trials to standard of care as an effective treatment for a broad range of tumor types.
Author List
Oldham RAA, Medin JAAuthor
Jeffrey A. Medin PhD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Clinical Trials as TopicDNA Transposable Elements
Genetic Therapy
Humans
Lentivirus
Leukemia
Neoplasms
Protein Domains
Receptors, Antigen, T-Cell
Recombinant Fusion Proteins
Retroviridae
